Related Experiment Video
Updated: Aug 18, 2025

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global
Howard C Margolese1,2,3, Matthieu Boucher4,5, Francois Therrien4
1Schizophrenia Program, McGill University Health Centre, Montreal, QC, Canada. howard.margolese@mcgill.ca.
Background:
ReLiAM, Real-Life Assessment of Abilify Maintena, was the first reported long-term prospective non-interventional study for patients with schizophrenia treated with aripiprazole once-monthly injectable formulation (AOM) under real-life conditions. ReLiAM's primary aim was to evaluate the evolution of global functional status in patients treated with AOM for 12 months in Canada.
Methods:
The objective of this post hoc analysis of the ReLiAM study is to investigate the treatment effects of real-life use of AOM over a 1-year period in the subgroup of patients with reported substance use compared with patients without substance use.
Results:
The results of this post hoc analysis demonstrate that treatment with AOM for 12 months in patients with schizophrenia was comparably effective in improving global functioning in subgroups of patients with and without concomitant substance use.
Conclusions:
These results support the use of AOM for the treatment of schizophrenia in patients with or without concomitant substance use.
Trial Registration:
ClinicalTrials.gov NCT02131415, first posted on May 6, 2014. Overall trial status: Terminated.
Related Concept Videos
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Psychosis and Antipsychotic Drugs: Overview
Antipsychotic Drugs: Typical and Atypical Agents
Antidepressant Drugs: MAOIs and Other Agents
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

